A second plausible explanation for resistance to the novel immunotherapies might be the tumor-intrinsic oncogenic signals such as active β-catenin signaling, that mediate T-cell exclusion at the site of the tumor and thus resistance to anti-PD-L1/anti-CTLA-4 therapy [38, 60]. The gene discussed is CTLA4; the disease is neoplasm.